Economic analysis of tirilazad mesylate for aneurysmal subarachnoid hemorrhage - Economic evaluation of a phase III clinical trial in Europe and Australia

被引:19
作者
Glick, H
Willke, R
Polsky, D
Llana, T
Alves, WM
Kassell, N
Schulman, K
机构
[1] Univ Penn, Div Gen Internal Med, Philadelphia, PA 19104 USA
[2] Univ Virginia, Virginia Neurol Inst, Dept Neurosurg, Charlottesville, VA 22908 USA
[3] Pharmacia & Upjohn Inc, Kalamazoo, MI 49001 USA
[4] Covance, Hlth Econ & Outcomes Serv, Horsham RH12 4QD, W Sussex, England
[5] Georgetown Univ, Med Ctr, Clin Econ Res Unit, Washington, DC 20007 USA
关键词
D O I
10.1017/S026646230001059X
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
This study used data from a multinational phase III randomized, double-blind, vehicle-controlled trial to evaluate the cost-effectiveness of tirilazad mesylate (Freedox(R)) in the treatment of aneurysmal subarachnoid hemorrhage. In men, therapy with 6 mg/kg per day of tirilazad mesylate was associated with significantly increased survival, increased cost of care, and ratios of cost per death averted that compare favorably with the ratios of other life and death interventions. In women, it appeared to have no effects on costs or survival. Further clinical studies may provide additional information about the cost-effectiveness of this intervention.
引用
收藏
页码:145 / 160
页数:16
相关论文
共 27 条
[1]  
ASHWAL S, 1994, NEW ENGL J MED, V330, P1499
[2]  
BARNETT GH, 1993, CURRENT MANAGEMENT C
[3]  
DENINO LA, 1993, J CURRENT CLIN TRIAL, P44
[4]  
Drummond M F, 1991, Int J Technol Assess Health Care, V7, P561
[6]  
EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144
[7]   BOOTSTRAP CONFIDENCE-INTERVALS FOR A CLASS OF PARAMETRIC PROBLEMS [J].
EFRON, B .
BIOMETRIKA, 1985, 72 (01) :45-58
[8]  
EFRON B, 1983, AM STAT, V37, P336
[9]  
EISENBERG JM, 1989, PHARMACOEPIDEM DR S, P325
[10]  
GARRAWAY WM, 1983, MAYO CLIN PROC, V58, P520